Titolo/oggetto del contratto di sperimentazione
SQUINT - FoRT 04 “(Squamous Immunotherapy Nivolumab-Ipilimumab Trial): An open-label, randomized, phase II trial of nivolumab plus ipilimumab versus platinum-based chemotherapy in chemonaive metastatic or recurrent Squamous-Cell Lung Cancer